Interleukin-6 pathway blockade as an option for managing refractory cases of crystal arthritis: Two cases report

Joint Bone Spine. 2018 May;85(3):377-378. doi: 10.1016/j.jbspin.2017.04.008. Epub 2017 May 9.

Authors

Neus Quilis¹, Mariano Andrés², Paloma Vela², Eliseo Pascual²

Affiliations

¹ Sección de Reumatología, Hospital Universitario Vinalopó, Elche, Alicante, Spain. Electronic address: [email protected].
² Sección de Reumatología, Hospital General Universitario de Alicante, Alicante, Spain; Departamento de Medicina Clínica, Universidad Miguel Hernández, Alicante, Spain.

PMID: 28499890
DOI: 10.1016/j.jbspin.2017.04.008

No abstract available

Keywords: Crystal-related arthritis; Tocilizumab.

Publication types

Case Reports
Letter

MeSH terms

Aged
Aged, 80 and over
Antibodies, Monoclonal, Humanized / therapeutic use*
Crystal Arthropathies / diagnosis
Crystal Arthropathies / drug therapy*
Female
Follow-Up Studies
Humans
Pain Measurement
Receptors, Interleukin-6 / drug effects*
Risk Assessment
Severity of Illness Index
Treatment Outcome

Substances

Antibodies, Monoclonal, Humanized
Receptors, Interleukin-6
tocilizumab